ReviewCurrent drug discovery technologies2026
Theranostic Applications of Microrobots: Integrating Diagnostics and Precision Drug Delivery.
Review in Current drug discovery technologies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A game-changing strategy in precision medicine is theranostics, which is the combination of diagnostics and treatments on one platform. Microrobots have drawn a lot of interest as promising agents in theranostic applications because of their small size, agility, and multifunctionality. This analysis highlights the potential of microrobots to transform illness management by examining how they can integrate precise medicine delivery and diagnostic capabilities. Advanced features like imaging for focused diagnostics, payload delivery for precision therapies, and biosensing for real-time disease monitoring can be built into microrobots. These microrobots can navigate intricate biological environments and provide localized intervention at the cellular and subcellular levels. They are propelled by external pressures such as magnetic fields or biological mechanisms. Recent advancements in microrobots, including biocompatible polymers and stimuli-responsive systems, offer potential for early disease identification and targeted drug release in neurological, cardiovascular, and malignant diseases. Along with solutions, issues like scalability, regulatory approval, and biocompatibility are also covered. With an emphasis on their role in influencing the development of integrated healthcare solutions, this paper offers a thorough summary of technological developments and potential applications of microrobots in theranostics. The study authors examined databases such as PubMed, Scopus, Google Scholar, ScienceDirect, and Web of Science for peer-reviewed articles published within the last 10 years on theranostic microrobots, diagnostic tools, drug delivery systems, and precision medicine. It comprised empirical research on microrobot design, functioning, therapeutic applications, diagnostic capabilities, treatment results, and safety profiles. This methodical methodology found patterns, gaps, and advances in the discipline.
Indexed as
Identifiers
40660435What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.